Status:

NOT_YET_RECRUITING

Postoperative Electrical Muscle Stimulation Two

Lead Sponsor:

University of Nottingham

Collaborating Sponsors:

University Hospitals of Derby and Burton NHS Foundation Trust

Conditions:

Surgery

Colorectal Cancer

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Undesirable loss of skeletal muscle mass (atrophy) is a common feature of many diseases as well as ageing, bed rest and physical inactivity. Losing muscle can lead to a reduction in one's ability to p...

Detailed Description

The main objective of this trial is to assess whether neuromuscular stimulation (NMES) can minimise muscle loss following abdominal surgery for cancer; and whether such effect is further improved by s...

Eligibility Criteria

Inclusion

  • Adult patients (age 18 or over at the time of diagnosis made at MDT (multi-disciplinary team meeting)
  • MDT outcome of colorectal or gastric cancer or non-invasive neoplasia (tissue-proven, or radiologically diagnosed and clinically suspected) with the intention to treat with curative abdominal surgery
  • Agreed management plan for open or minimally invasive (laparoscopic or robot assisted) segmental abdominal (colonic or gastric) resection at the Royal Derby Hospital
  • Sufficient mobility and fitness to complete normal ERAS (enhanced recovery after surgery) protocols following surgery
  • Basic conversational spoken English language
  • Ability to give informed consent

Exclusion

  • Upper GI (gastrointestinal) cancer requiring thoracotomy/thoracoscopy
  • Pre-existing neuromuscular disease (including Parkinsons disease)
  • Pacemaker, implantable cardiac defibrillator or other implanted nerve stimulator device
  • Metal prostheses or other metal-work in either upper legs (hip/knee/femur)
  • Dementia or other cognitive problem or language barrier causing an inability to follow instructions and operate NMES machine
  • Inability to give informed consent
  • Disability preventing completion of ERAS after surgery (requiring Zimmer frame/wheeled frame/wheelchair to mobilise or bed-bound)
  • Peripheral vascular disease
  • Epilepsy
  • Pre-existing diagnosis of chronic kidney disease or estimated glomerular filtration rate \<60 on screening visit
  • Pre-existing diagnosis of liver disease
  • Intubation or intensive care admission during study period (between day 0-5 post-op); (surgical high dependency unit patients will be included)
  • Return to theatre for surgical complication within first 5-days post operation
  • History of rhabdomyolysis
  • Pregnancy
  • Deep vein thrombosis within past 6-months
  • Allergy to whey protein
  • Patient refusal of whey protein products on grounds of dietary requirements or intolerance
  • Participating in another clinical trial concurrently or within the last 6 months
  • Known infection with blood borne virus

Key Trial Info

Start Date :

May 1 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 1 2026

Estimated Enrollment :

45 Patients enrolled

Trial Details

Trial ID

NCT06964438

Start Date

May 1 2025

End Date

July 1 2026

Last Update

May 9 2025

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.